Does VISMODEGIB Cause Malignant neoplasm progression? 18 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 18 reports of Malignant neoplasm progression have been filed in association with VISMODEGIB (ERIVEDGE). This represents 0.2% of all adverse event reports for VISMODEGIB.
18
Reports of Malignant neoplasm progression with VISMODEGIB
0.2%
of all VISMODEGIB reports
2
Deaths
4
Hospitalizations
How Dangerous Is Malignant neoplasm progression From VISMODEGIB?
Of the 18 reports, 2 (11.1%) resulted in death, 4 (22.2%) required hospitalization, and 2 (11.1%) were considered life-threatening.
Is Malignant neoplasm progression Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for VISMODEGIB. However, 18 reports have been filed with the FAERS database.
What Other Side Effects Does VISMODEGIB Cause?
Muscle spasms (1,937)
Alopecia (1,330)
Ageusia (958)
Fatigue (899)
Dysgeusia (706)
Weight decreased (688)
Nausea (669)
Decreased appetite (662)
Death (657)
Diarrhoea (446)
What Other Drugs Cause Malignant neoplasm progression?
PEMBROLIZUMAB (10,111)
NIVOLUMAB (9,363)
ENZALUTAMIDE (4,696)
CARBOPLATIN (4,177)
EVEROLIMUS (3,789)
PACLITAXEL (3,484)
LETROZOLE (3,445)
IPILIMUMAB (3,296)
FULVESTRANT (3,221)
LENVATINIB (2,929)
Which VISMODEGIB Alternatives Have Lower Malignant neoplasm progression Risk?
VISMODEGIB vs VITAMIN A
VISMODEGIB vs VITAMIN B
VISMODEGIB vs VITAMIN D NOS
VISMODEGIB vs VITAMINS
VISMODEGIB vs VOCLOSPORIN